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Calpastatin is an endogenous specific inhibitor of calpain, a calcium-dependent 46 
cysteine protease. Here we show that loss-of-function mutations in the calpastatin 47 
gene (CAST) are the genetic cause of an autosomal recessive condition characterized 48 
by generalized peeling skin, leukonychia, acral punctate keratoses, cheilitis and 49 
knuckle pads (PLACK syndrome). In affected individuals with PLACK syndrome 50 
from three families of different ethnicities, we identified homozygous mutations 51 
(c.607dup, c.424A>T and c.1750delG) in CAST, all of which were predicted to 52 
encode truncated proteins (p.Ile203Asnfs*8, p.Lys142* and p.Val584Trpfs*37). 53 
Immunocytochemistry shows that expression of calpastatin is reduced in skin from 54 
affected individuals. Transmission electron microscopy revealed widening of 55 
intercellular spaces with chromatin condensation and margination in the upper stratum 56 
spinosum in lesional skin, suggesting impaired intercellular adhesion as well as 57 
keratinocyte apoptosis. A significant increase of apoptotic keratinocytes was also 58 
observed in TUNEL assays. In vitro studies utilizing siRNA-mediated CAST 59 
knockdown revealed a role for calpastatin in keratinocyte adhesion. In summary, we 60 
describe PLACK syndrome, as a novel clinical entity of defective epidermal adhesion, 61 
caused by loss-of-function mutations in the CAST gene.  62 




MAIN TEXT 67 
Peeling skin syndrome (PSS) is characterized by continuous shedding of the stratum 68 
corneum of the epidermis with onset from birth or infancy and lasting throughout 69 
life.
1
 Skin peeling may be accompanied by erythema, vesicular lesions, or other 70 
ectodermal features including fragile hair and nail abnormalities.
2
 PSS can be divided 71 
into two clinical forms: acral PSS (APSS, MIM 609796) and generalized PSS (GPSS, 72 
MIM 270300). APSS involves the palmar, plantar and dorsal surfaces of hands and 73 
feet and can be associated with mutations in the transglutaminase 5 gene (TGM5, 74 
MIM 603805).
3
 In addition, mutations in the gene encoding for the cysteine protease 75 
inhibitor cystatin A (CSTA, MIM 184600) have recently been associated with 76 
autosomal recessive exfoliative ichthyosis (MIM 607936) and also APSS.
4,5
 77 
Individuals with inflammatory GPSS associated with mutations in the 78 
corneodesmosin gene (CDSN, MIM 602593) can also present with severe pruritus, 79 
food allergies and repeated episodes of angioedema, urticaria, and asthma.
6
 A 80 
homozygous missense mutation was identified within the CHST8 gene (MIM 610190), 81 
encoding N-acetylgalactosamine-4-O-sulfotransferase, in a large consanguineous 82 
family with non-inflammatory GPSS.
7
 However, the genetic basis of a number of PSS 83 




Here we show that homozygous loss-of-function (LOF) mutations in the CAST 86 
gene underlie autosomal recessive generalized PSS with leukonychia, acral punctate 87 
keratoses, cheilitis and knuckle pads. We propose this novel clinical entity to be given 88 
the acronym PLACK syndrome. Using exome sequencing and Sanger sequencing we 89 
demonstrate that distinct homozygous LOF CAST gene mutations segregate with the 90 
disorder in all three families with PLACK syndrome. CAST encodes calpastatin, an 91 
endogenous protease inhibitor. Our findings emphasize the important role of the 92 
protease-inhibitor balance in epidermal homeostasis. 93 
 94 
We ascertained a 28-year-old Chinese female (individual 1) affected with PLACK 95 
syndrome who was born to second-cousin parents (Figure 1A). She was found to have 96 
trauma-induced recurrent blistering prominently on the extremities since infancy, 97 
which was worse in summer. In winter, asymptomatic skin peeling was more 98 
prominent, either spontaneously or following the remission of blistering, leaving 99 
underlying erythema. The blistering improved and was confined to distal extremities 100 
after puberty, while skin peeling progressed to involve nearly the entire body. She had 101 
mild pruritus and no history of atopy. Physical examination revealed generalized dry, 102 
scaly skin with superficial exfoliation and underlying erythema (Figure 1B). Cheilitis 103 
with dry, shedding scales was observed (Figure 1B). Several blisters were noted on 104 
her wrists and soles. Punctate palmoplantar keratoderma was seen, which coalesced 105 
into focal keratoderma predominately on the weight-bearing areas (Figure 1B). 106 
Knuckle pads with multiple hyperkeratotic micropapules were also found involving 107 
all the interphalangeal joints. Leukonychia affected the proximal half of the nails with 108 
mild distal onycholysis (Figure 1B). No other systemic abnormalities were identified. 109 
Histological examination of a biopsy from the scaly skin of her leg showed 110 
hyperkeratosis, acanthosis, intraepidermal clefting with irregular acantholysis (Figure 111 
1C).  112 
 113 
We also investigated an affected Nepalese female (individual 2) from 114 
non-consanguineous parents who presented to dermatologists at age 3 with a 2-year 115 
history of painful lesions on the palms and soles. Clinical examination revealed 116 
punctate keratoses on the palms, extending onto the flexor aspect of the wrists and 117 
soles, plaques with hyperkeratotic micropapules over the interphalangeal joints, 118 
cheilitis of the upper lip and angular cheilitis, subtle telangiectasia on the cheeks, 119 
follicular hyperkeratosis on the extensor surface of the knees and leukonychia of 120 
70-100% of the nails (Figure 1D and Figure S1, available online). At review at age 4, 121 
peeling areas had developed on the distal limbs including the extensor surface of the 122 
knees and elbows (Figure 1D). 123 
 124 
An additional family with known consanguinity, previously reported as having a 125 
recessive form of pachyonychia congenita, was also enrolled in this study.
10
 Briefly, 126 
both affected Caucasian male siblings (individuals 3 and 4, now age 54 and 58 years 127 
old) give a history of blistering and peeling of skin from the age of about 3 months on 128 
the hands, feet, knuckles, elbows and knees. Skin fragility is induced by minor trauma 129 
and heat and continues to be the greatest problem for these individuals. Both 130 
individuals also have leukonychia, leukokeratosis, angular cheilitis, papules on the 131 
extensor surface of the fingers and toes and punctate palmar keratosis and a plantar 132 




This project was approved by the Clinical Research Ethics Committee of the 135 
Peking University First Hospital, East London and City Health Authority Research 136 
Ethics Committee and the Western Institutional Review Board which all comply with 137 
all principles of the Helsinki Accord.  138 
 139 
We collected blood and saliva samples from the three families after obtaining 140 
informed consent. After exclusion of pathogenic mutations in TGM5, CSTA, CDSN 141 
and CHST8 by Sanger sequencing, we performed exome sequencing in individual 1 142 
using 3 μg of genomic DNA. Exome capture was performed with the Nimblegen 143 
SeqCap EZ Library (Roche) for enrichment and then sequenced on an Illumina 144 
HiSeq2000 according to the manufacturer’s protocols. Variants were filtered against 145 
dbSNP137, the 1000 Genomes Project, HapMap8 and BGI inner databases, as 146 
described in our previous study.
9
 As her parents were consanguineous, we focused on 147 
homozygous variants to identify the causative gene. Among all the 148 variants 148 
fulfilling these criteria, only 15 variants lay in coding exons or splicing boundaries 149 
and were predicted to be “not tolerated” by SIFT.
11
 These included a one-nucleotide 150 
duplication in CAST which was predicted to lead to a frameshift and truncation of the 151 
protein. By Sanger sequencing (primers are listed in Table S1, available online), we 152 
confirmed that this mutation c.607dup (p.Ile203Asnfs*8; RefSeq accession number 153 
NM_001042440.3, NP_001035905.1) was homozygous in individual 1 and 154 
heterozygous in her unaffected parents, siblings and daughters (Figures 1A and 2A). 155 
This mutation was not found in 200 ethnically matched controls.  156 
 157 
Exome sequencing was performed on genomic DNA from individual 2 using the 158 
NimbleGen
TM
 SeqCap EZ Library SR (Roche) and sequenced on an Illumina 159 
HiSeq2000 according to the manufacturer’s protocols. Further details of analysis are 160 
described previously.
11
 Analysis of novel variants revealed a homozygous nonsense 161 
mutation c.424A>T (p.Lys142*) in CAST. Sanger sequencing showed co-segregation 162 
with the disorder in this family (Figure 2A and Figure S1A). Subsequent exome 163 
sequencing and Sanger sequencing also showed a homozygous frameshift mutation 164 
c.1750delG (p.Val584Trpfs*37) in CAST in individuals 3 and 4, which co-segregated 165 
with the disorder in the family (primers are listed in Table S1).  166 
 167 
All three mutations identified in CAST are predicted to encode truncated proteins 168 
and lead to a loss of function. To investigate the consequences of homozygosity for 169 
the c.607dup mutation in vivo, we examined the mRNA expression of CAST in the 170 
skin from individual 1 by using quantitative real-time PCR (qRT-PCR) (primers are 171 
listed in Table S2). The level of CAST transcription was determined on the basis of 172 
the comparative cycle threshold (2
-
△△
Ct) method using cDNA templates generated 173 
from a corresponding area of the skin from a gender and age-matched healthy control 174 
as the calibrator. In contrast to the control, we could only detect trace expression of 175 
CAST mRNA in individual 1, probably due to mechanisms of nonsense-mediated 176 
mRNA decay (Figure 2B). Immunohistochemical staining was subsequently 177 
performed using a calpastatin antibody (catalog number: sc-20779, Santa Cruz) in 178 
paraffin-embedded sections from the pretibial skin lesion of individual 1. A similar 179 
analysis was performed on paraffin-embedded sections taken from xerotic left thigh 180 
skin of individual 2, but using immunofluorescence. Consistent with the predicted 181 
effect of the two mutations and the results of the qRT-PCR analysis of the c.607dup 182 
mutation, calpastatin expression was absent/reduced in the skin from both individuals, 183 
whereas in the normal control skin calpastatin is localized throughout the epidermis 184 
and has a cytoplasmic localization (Figure 2C and Figure S2). No skin biopsy material 185 
was available from individuals 3 or 4. 186 
 187 
  Calpastatin is a specific endogenous protease inhibitor of calpains (µ-calpain and 188 
m-calpain). Calpains are intracellular cysteine proteases that require calcium or 189 
epidermal growth factor for their catalytic activity.
12
 In skin, calpains have been 190 
reported as being involved in a range of cellular processes, including keratinocyte 191 
growth, migration and cell cycle regulation.
13
 These processes are particularly 192 
important in epidermal terminal differentiation, characterized by expression of 193 
specific structural proteins. Previous studies have shown that calpains can degrade 194 
filaggrin to peptides.
14
 Immunohistochemical staining of lesional skin sections from 195 
individual 1 demonstrated that filaggrin expression (antibody catalog number: 196 
sc-66192, Santa Cruz) was markedly reduced compared to control (Figures 3A and 197 
3B). The degradation of filaggrin could explain, at least in part, the ichthyosiform 198 
cutaneous changes. A slight upregulation of loricrin (antibody catalog number: 199 
ab24722, Abcam), keratin 1 (antibody catalog number: ab24643, Abcam) and keratin 200 
10 (antibody catalog number: ab76318, Abcam) was also observed in the lesional skin 201 
from individual 1 (Figure S3). The increased expression of these proteins may be a 202 
compensatory mechanism for epidermal barrier disruption.
15
  203 
 204 
  As increased activity of calpains can induce apoptosis,
16
 in situ apoptotic 205 
examination of keratinocytes in the lesional skin biopsy from individual 1 was 206 
performed using a TUNEL assay (In Situ Cell Death Detection Kit, Roche). Skin 207 
sections from an unrelated healthy subject were used as a control. Images above the 208 
stratum basale were taken randomly with a fluorescence microscope (IX71, Olympus, 209 
Tokyo, Japan), using the same settings for both control and individual skin sections. 210 
Total cells and apoptotic cells (with fluorescent nuclei) in five random high-power 211 
fields (400X) were counted. The number of apoptotic cells in the imaged fields was 212 
significantly increased in lesional skin compared to normal control (Figures 3C and 213 
3D). Ultrastructural analysis of lesional skin sections from individual 1 was 214 
performed by transmission electron microscope (TEM), which showed expanded 215 
intercellular spaces (Figure 3E), apoptotic chromatin condensation and margination 216 
(Figure 3F), supporting the results of the TUNEL assay.  217 
 218 
To determine the functional consequences of CAST LOF mutations in vitro, we 219 
performed siRNA-mediated knockdown (KD) of CAST using a specific siRNA pool 220 
(ON-TARGETplus Human CAST siRNA-SMARTpool, GE Healthcare Dharmacon) 221 
in the immortalized keratinocyte cell line, HaCaT. Non-targeting pool siRNA 222 
(ON-TARGETplus Non-targeting Pool, GE Healthcare Dharmacon) was used as a 223 
control. Immunocytochemistry on HaCaT cell monolayers treated with CAST siRNA 224 
and analysis of total protein lysates by western blotting showed robust CAST 225 
knockdown (Figures 4A-4C).  226 
 227 
We then used an in vitro mechanical-induced stress assay to investigate the role of 228 
calpastatin in keratinocyte adhesion in CAST siRNA-treated cells (CAST KD cells) 229 
and NTP siRNA-treated cells (NTP cells). For this we have used the Flexcell FX-4000 230 
Tension System (Flexcell, Hillsborough, NC) which uses vacuum pressure to apply 231 
cyclic or static strain to cells cultured on flexible-bottomed culture plates. CAST KD 232 
cells (mimicking the homozygous LOF mutations) and NTP cells were subjected to 233 
mechanical stretch at a frequency of 5 Hz (five cycles of stretch and relaxation per 234 
second) and an elongation of amplitude ranging from 10% to 14% (increase in 235 
diameter across the silicone deformable membrane from 10% to 14%). Cells were 236 
stretched for 0 hr (non-stretched) and 4 hr. Immunocytochemistry with an in-house 237 
LL001 monoclonal keratin 14 antibody
17
 on siRNA-treated cells pre- and 238 
post-mechanical stress revealed breakage of the intercellular connections in CAST 239 
KD cell monolayers independent of whether they had been subjected to mechanical 240 
stress. In contrast, NTP cells presented with stretched keratin filaments post-stretching 241 
but no disruption in intercellular adhesion prior to mechanical stress (Figures 4D-4G).  242 
 243 
A recent study by Nassar et al. looking at calpastatin overexpression in a mouse 244 
model reported significant changes in the wound-healing process compared to normal 245 
mice.
18
 Calpastatin overexpression mice showed a striking delay in wound-healing 246 
with reduced proliferation and re-epithelialization, particularly in the early steps of the 247 
wound-healing process.
18
 The possible effects of CAST LOF mutations on 248 
keratinocyte migration were assessed by performing a scratch assay on CAST KD cell 249 
monolayers compared to NTP cells. As CAST KD scratch-wounds appeared to close 250 
at the same rate as NTP scratch-wounds, we concluded that cell migration in 251 
monolayers was not altered by CAST knockdown in 3 independent experiments 252 
(Figure S4).  253 
 254 
Following observations in CAST LOF skin and our in vitro studies indicating a key 255 
role for calpastatin in keratinocyte adhesion, we examined desmosomal protein 256 
expression. Immunofluorescence with an antibody targeting Desmoplakin (DSP; 257 
11-5F mouse monoclonal, a gift from David Garrod),
19
 the major protein of the 258 
desmosome, was performed on frozen skin sections from individuals 1 and 2. This 259 
showed an apparent increase in DSP expression, with both a plasma membrane and 260 
cytoplasmic localization pattern compared to a specific membranous localization 261 
pattern in control skin (Figures 4H and 4I and Figures S3G and S3H). Furthermore, 262 
our in vitro studies displayed a general trend of DSP upregulation in CAST KD cells 263 
independent of mechanical stress when compared to NTP cells (data not shown). 264 
 265 
Calpain and its endogenous specific inhibitor calpastatin constitute an intracellular 266 
non-lysosomal proteolytic system ubiquitously expressed in mammals and many other 267 
organisms. By catalyzing the controlled proteolysis of target proteins, calpains play an 268 
important role in various cell functions, including cell proliferation, differentiation, 269 
mobility, cell cycle progression, as well as cell-type specific functions like cell fusions 270 
in myoblasts.
20,21
 Also, activation of calpains has been suggested to trigger apoptosis 271 
by cleaving either pro-apoptotic or anti-apoptotic proteins.
22
 It has been demonstrated 272 
in vitro that increased activity of m-calpain results in apoptosis of HaCaT cells.
23
 LOF 273 
mutations in CAST lead to disinhibition of calpains, thus enhancing apoptosis of 274 
keratinocytes, as showed in our TUNEL and TEM results. Elevated apoptotic levels of 275 
keratinocytes may result in skin hyperkeratosis,
24,25
 leading to the clinical phenotypes 276 
of acral punctate keratoses, knuckle pads with hyperkeratotic micropapules and 277 
leukonychia.  278 
 279 
Previous studies have shown that calpain could promote focal adhesion 280 
disassembly by proteolysis of talin and focal adhesion kinase.
26,27
 Our CAST KD 281 
experiments indicate that the calpain/calpastatin system may also be critical for 282 
intercellular adhesion. Increased calpain activity due to LOF mutations in CAST may 283 
lead to excessive proteolysis of epidermal desmosomal components, as demonstrated 284 
by aberrant expression of DSP in the affected individuals, resulting in acantholysis 285 
and impaired resistance of the epidermis to mechanical stretch (blistering and skin 286 
peeling). Although calpastatin was suggested to play diverse physiological roles in 287 
neurological, musculoskeletal and ocular systems,
28
 no significant related symptoms 288 
were observed in our affected individuals. Further studies are required to elucidate 289 
whether there is redundancy of the calpain proteolytic system in these organs, 290 
explaining the lack of abnormalities. Notably, Cast-knockout mice, which showed 291 
increased activity of calpains exhibit no defect under normal conditions
29
 but only 292 
slight behavioral changes in a stressful environment.
30
 These phenotypic differences 293 
indicate different physiological functions of the calpain/calpastatin system between 294 
humans and mice.  295 
 296 
In summary, we describe the clinical features of a new autosomal recessive entity 297 
termed PLACK syndrome with generalized skin peeling, leukonychia, acral punctate 298 
keratoses, cheilitis and knuckle pads, distinct from epidermolysis bullosa or 299 
pachyonychia congenita. In three families with this condition, homozygous LOF 300 
mutations in CAST were identified leading to reduced expression of calpastatin, the 301 
only known inhibitor of calpains. Mutations of protease inhibitors can disrupt the skin 302 
barrier, impair keratinocyte adhesion, affect cell signaling and cause various genetic 303 
skin conditions,
4,31
 such as Netherton syndrome (MIM 256500) caused by mutations 304 
in SPINK5 (MIM 605010),
32
 Nagashima-type palmoplantar keratosis (MIM 615598) 305 
caused by mutations in SERPINB7 (MIM 603357).
33,34
 Our findings expand the 306 
spectrum of these conditions and explore new avenues for proteolytic pathways in 307 
skin.  308 
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Figure Titles and Legends 465 
 466 
Figure 1. Clinical Findings of PLACK Syndrome 467 
(A) Family pedigree of individual 1. The arrow indicates individual 1 and W 468 
represents wild-type. (B) Individual 1 showed clinical features of generalized skin 469 
peeling, cheilitis, plantar keratoses on weight-bearing areas, blistering, leukonychia 470 
and knuckle pads with multiple hyperkeratotic micropapules. (C) Histopathology of 471 
skin biopsy from lower extremities of individual 1 demonstrated intraepidermal 472 
clefting with irregular acantholysis (hematoxylin-eosin staining, the scale bar 473 
represents 50 μm). (D) Similar clinical features were found in individual 2, including 474 
skin peeling, cheilitis, punctate keratoses of the soles, leukonychia and knuckle pads 475 
with hyperkeratotic micropapules.   476 
 477 
Figure 2. Homozygous Mutations in CAST and Its Expression in the Epidermis 478 
(A) Sequence chromatograms showing homozygous mutations c.607dup, c.424A>T 479 
and c.1750delG in the affected individuals. Arrows indicate the position of the 480 
mutation. (B) Homozygous frameshift mutation c.607dup-mediated mRNA decay of 481 
calpastatin in individual 1 is demonstrated by qRT-PCR compared to the normal 482 
control. The error bar represents the standard error of the mean (SEM). (C) 483 
Immunohistochemistry shows absent calpastatin expression in individual 1(right panel) 484 
compared to normal expression throughout the epidermis in the control (left panel). 485 
The scale bars represent 50 μm. 486 
Figure 3. Decreased Expression of Filaggrin and Increased Keratinocyte 487 
Apoptosis in Lesional Skin 488 
(A, B) Compared to the normal control (A), markedly reduced expression of filaggrin 489 
was noted in individual 1 (B). Scale bars represent 50 μm. (C, D) TUNEL assay 490 
demonstrated increased apoptotic level of keratinocytes in lesional skin from 491 
individual 1 (D) compared to the normal control (C). The scale bars represent 50 μm. 492 
(E) TEM of lesional skin from individual 1 showed expanded intercellular spaces 493 
(asterisks). (F) At higher magnification, chromatin condensation and margination 494 
were apparent.  495 
 496 
Figure 4. CAST Knockdown Decreases Intercellular Adhesion and Increases 497 
Desmoplakin Expression 498 
(A-C) HaCaT cells transfected with a pool of NTP siRNA (A) or CAST siRNA (B) 499 
were stained with an anti-calpastatin (green) antibody and DAPI (blue) as a nuclear 500 
marker. Total protein from HaCaT cell lysates after transfection with NTP siRNA 501 
(lane 1) or CAST siRNA (lane 2) were incubated with an anti-calpastatin antibody (C). 502 
GAPDH was used as loading control. A significant reduction in calpastatin protein 503 
levels can be observed in the CAST KD cells compared to NTP cells, both by 504 
immunocytochemistry and western blotting. (D-G) CAST KD and NTP cells were 505 
subjected to cyclic stretching for 0 hr (unstretched; D, F) and 4 hr (E, G) followed by 506 
staining with an anti-keratin 14 antibody. Stretching of the keratin filaments can be 507 
observed after 4 hr mechanical stress in the NTP cells (arrows) compared to 508 
unstretched monolayers. In the CAST KD cells breakage of these filaments together 509 
with widening of the intercellular spaces was observed independent of mechanical 510 
stress (asterisks). (H, I) Immunohistochemistry with an anti-desmoplakin antibody on 511 
skin sections from individual 2 revealed an upregulation and change in localization of 512 
this protein from a membranous appearance (H) to a both membranous and 513 
cytoplasmic appearance (I) in comparison to control. The scale bars on all images 514 
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Supplemental Text and Figures
 
 
Table S1. Primer Pairs for Confirmation of CAST Mutations 
 
 Forward Primers (5’-3’) Reverse Primers (5’-3’) 
c.607dup GCTTCTTGCCTGAATGTGGC CCATGGCCTTATTTGCTCTCC 
c.424A>T AATTTTGGGGGAAGGATTTG ATTGCTGGGCAGTAGGAGAA 





































Table S2. Primer Pair for qRT-PCR 
 
 Forward Primers (5’-3’) Reverse Primers (5’-3’) 


















Figure S1. Further Details of the Clinical Phenotype of Individual 2. 
(A) Pedigree of the family of individual 2 showing mutation segregation. The arrow 
indicates individual 2. (B) Overview of dorsum of hand showing knuckle pads on 
proximal and distal interphalangeal joints and leukonychia. (C) Scaly papule right ear 
antihelix. (D) Skin peeling with residual erythema left forearm. (E) Left foot showing 
leukonychia and papules with hyperkeratotic micropapules left second toe. (F) 
Punctate keratoses palm, most prominent along distal palmar creases. (G) 
Hyperkeratotic papules extensor surface of knees.      
 
Figure S2. Immunohistochemical Staining of Calpastatin in the Epidermis of 
Individual 2 and the Normal Control 
(A, B) Immunofluorescent staining of calpastatin (green) showed that calpastatin 
expression is reduced in individual 2 (B) compared to normal control (A). DAPI was 
















Figure S3. Immunohistochemical Staining of Terminal Differentiation Markers 
and Desmoplakin in the Epidermis of Individual 1 and the Normal Control 
Keratin 1 (A), keratin 10 (C) and loricrin (E) of individual 1 showed normal 
distribution with slightly increased expression in the upper epidermis compared with 
the normal control (B, D, F). Desmoplakin expression was upregulated in individual 1 
with an abnormal cytoplasmic localization (G) compared to the normal control (H). 



















Figure S4. Scratch Assay 
No significant difference was observed between NTP siRNA and CAST siRNA 
treated cells suggesting that there is no significant increase in cell migration and 
scratch closure (n=8 from 3 independent experiments). 
